Yearly Prostate Specific Antigen and Digital Rectal Examination Fluctuations in a Screened Population
Purpose
Prostate biopsy is often recommended based on increases in prostate specific antigen and/or abnormal digital rectal examination. We investigated the stability of a single positive test during the next 3 consecutive years.
Materials and Methods
A total of 2,578 participants in a San Antonio screening cohort with 2 or more consecutive annual prostate specific antigen and digital rectal examination tests were identified. Occurrences of an increased prostate specific antigen (2.5 ng/ml or greater) followed by 1 or more nonincreased prostate specific antigen results were compared with similar fluctuations of digital rectal examination from abnormal to normal.
Results
In 2,272 men who did not have a biopsy during the study, in 23.3% of 744 incidences of an increased prostate specific antigen with 1 year of followup, the next prostate specific antigen was not increased. In 19.5% of 462 incidences of an increased prostate specific antigen with 2 years of followup, the next 2 consecutive prostate specific antigen levels were not increased. Finally, in 17.5% of 285 incidences of an increased prostate specific antigen with 3 years of followup, the next 3 consecutive prostate specific antigens were not increased. Rates were similar but lower in 221 men with 1 or more negative biopsies during the study and in 85 men in whom prostate cancer eventually developed during the study. In contrast, approximately 70% of abnormal digital rectal examinations were normal the following year even in patients with prostate cancer, and in the majority of incidences remained normal the next 2 to 3 consecutive years.
Conclusions
Occurrences of reversed prostate specific antigen cut point or abnormal digital rectal examination based decisions to biopsy 1 or more years after the initial test are not uncommon, suggesting repetition of these tests.
Key Words: prostate-specific antigen, digital rectal examination, time factors
Abbreviations and Acronyms: DRE, digital rectal examination, PSA, prostate specific antigen, SABOR, San Antonio Center of Biomarkers of Risk for Prostate Cancer
To access this article, please choose from the options below
Supported by U.S. Public Health Service Grants awarded by the National Cancer Institute, Department of Health and Human Services CA 37429, CA 35178, CA 45808, CA 86402 and 5UO1CA86402 (Early Detection Research Network, National Cancer Institute, National Institutes of Health).
Editor's Note: This article is the third of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 2392 and 2393.
PII: S0022-5347(09)00051-2
doi:10.1016/j.juro.2009.01.029
© 2009 American Urological Association. Published by Elsevier Inc. All rights reserved.

